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ttp://dx.doi.org/10.1016/j.jmoldx.2014.06.001Next-generation sequencing shows great promise by allowing rapid mutational analysis of multiple
genes in human cancers. Recently, we implemented the multiplex PCR-based Ion AmpliSeq Cancer
Hotspot Panel (>200 amplicons in 50 genes) to evaluate EGFR, KRAS, and BRAF in lung and
colorectal adenocarcinomas. In 10% of samples, automated analysis identiﬁed a novel G873R sub-
stitution mutation in EGFR. By examining reads individually, we found this mutation in >5% of
reads in 50 of 291 samples and also found similar events in 18 additional amplicons. These apparent
mutations are present only in short reads and within 10 bases of either end of the read. We
therefore hypothesized that these were from panel primers promiscuously binding to nearly com-
plementary sequences of nontargeted amplicons. Sequences around the mutations matched primer
binding sites in the panel in 18 of 19 cases, thus likely corresponding to panel primers. Furthermore,
because most primers did not show this effect, we demonstrated that next-generation sequencing
may be used to better design multiplex PCR primers through iterative elimination of offending
primers to minimize mispriming. Our results indicate the need for careful sequence analysis to avoid
false-positive mutations that can arise in multiplex PCR panels. The AmpliSeq Cancer panel is a
valuable tool for clinical diagnostics, provided awareness of potential artifacts. (J Mol Diagn 2014,
16: 541e549; http://dx.doi.org/10.1016/j.jmoldx.2014.06.001)Supported by grants from the Caring Collection (C.D.G.), the Johns
Hopkins Hospital Women’s Board (M.T.L.), NIH grant R21CA164592
(J.R.E.), and a PanCan/AACR Innovation Award (J.R.E.).
Disclosures: None declared.Detecting driver mutations in cancer genomes is of
increasing importance for patient care, both for prognostic
signiﬁcance and for allowing better utilization of targeted
therapies. Determining the mutational status of speciﬁc
genes, such as KRAS, BRAF, and EGFR in lung adenocar-
cinoma and KRAS and BRAF in colorectal adenocarcinoma,
has become the standard of care in clinical oncology to direct
epidermal growth factor receptor (EGFR) inhibitor ther-
apy.1,2 To achieve this, targeted sequencing of these genes
with the use of Sanger sequencing and pyrosequencing is
widely available. However, Sanger sequencing is labor
intensive and has a relatively poor analytic sensitivity
(approximately 20% mutant alleles), requiring specimens
with a signiﬁcant percentage of tumor nuclei (>40%) to
detect heterozygous mutations.3,4 Pyrosequencing, although
less labor intensive with a better limit of detection (analytic
sensitivity approximately 5%), is typically limited to shortstigative Pathology
.regions of DNA, requiring the clustering of mutations (eg,
KRAS codons 12 and 13). With each of these approaches, a
single amplicon from a single patient is analyzed in a single
well or capillary.
Massively parallel, next-generation sequencing (NGS)
platforms, such as the Ion Torrent Personal Genome Machine
(PGM) and the Illumina MiSeq, provide limits of detection
superior to pyrosequencing combined with even broader
genomic coverage.5e7 Although NGS platforms have the
capability to perform cancer whole genome/exome sequencing,
targeted sequencing of panels of amplicons with actionable and
hotspot mutations is currently more practical in a clinical
McCall et allaboratory setting.8e11 One panel, the Ion Torrent AmpliSeq
Cancer Hotspot Panel, uses multiplex-PCR to cover >200
amplicons in 50 genes known to be involved in carcinogenesis.
We recently transitioned to this platform to determine KRAS,
BRAF, and EGFR mutation status in formalin-ﬁxed, parafﬁn-
embedded (FFPE) lung and colon cancer specimens.
A major issue with FFPE specimens is signiﬁcant vari-
ability in both the quality and quantity of DNA that can be
isolated. Sources of this variability include the amount of
tumor in the biopsy, time from biopsy/resection to ﬁxation,
and time in formalin before processing.12,13 As a result, we
often are left with relatively low DNA concentrations,
which may require use of less DNA than the recommended
10- to 30-ng amount for the AmpliSeq panel.
Here, we report that off-target ampliﬁcation is common in
multiplex-PCRebased NGS, yielding 19 mispriming events
in 208 amplicons (9%) in our study. We deﬁne the signature
features to identify mispriming events and show that false-
positive mutations can be avoided by using multiple bio-
informatic analysis tools in the pipeline. We also show that
these events are more common with lower input DNA
amounts. We demonstrate that the phenomenon is due to
multiplex PCR and is not seen when primers are used in
monoplex reactions. Finally, because the vast majority of
primers do not show signiﬁcant mispriming, we hypothesize
that NGS may be the ultimate multiplex PCR primer design
tool by allowing for sensitive detection of off-target ampliﬁ-
cation and consequent iterative primer design.
Materials and Methods
Materials
As a part of ongoing clinical diagnosis of mutations in lung
and colorectal adenocarcinomas at The Johns Hopkins Hos-
pital, 291 consecutive FFPE tissue specimens were analyzed
during a 6-month period from January to June 2013. In addi-
tion, 10 FFPE tissue specimens from a variety of tissue types
were analyzed at Duke University Hospital. The tumor tissues
were enriched bymanual dissection of targeted areas identiﬁed
by anatomical pathologists as described previously.3 DNA
was isolated as described previously.3,14 Concentration of
DNA was determined by Qubit 2.0 Fluorometer (Life Tech-
nologies, Carlsbad, CA).
NGS
The NGS was conducted with the Ion AmpliSeq Cancer
Hotspot Panel version 2 for targeted multigene ampliﬁcation
[207 amplicons covering approximately 2800 Catalog of So-
matic Mutations in Cancer (COSMIC, http://cancer.sanger.
ac.uk/cancergenome/projects/cosmic, last accessed July 14,
2014) mutations from 50 oncogenes and tumor suppressor
genes], Ion AmpliSeq Library Kit 2.0 for library preparation,
Ion OneTouch 200 Template Kit version 2 DL and Ion
OneTouch ES Instrument for emulsion PCR and enrichment,542Ion PGM 200 Sequencing Kit, Ion 318 Chips, and the PGM
sequencing platform for massive parallel sequencing (Life
Technologies), as recommended by the manufacturers’
protocols without modiﬁcation. The DNA input for targeted
multigene PCRwas 0.8 to 30 ng. Up to eight specimens were
barcoded with Ion Xpress Barcode Adapters (Life Tech-
nologies), pooled, and run on a single Ion 318 chip. This
includes multiple patient samples and one control, which we
rotate among water, normal, and a mix of positive control
cell lines.
Analysis Pipeline
Sequencing data of three targeted genes that we have
validated in clinical practice (KRAS, BRAF, and EGFR)
were analyzed with Torrent Suite version 3.2.0 (Life
Technologies). All other genes were masked for this anal-
ysis in Torrent Variant Caller by using speciﬁc BED ﬁles
and in Ion Reporter using ﬁlters. Mutations were identiﬁed
and annotated through Torrent Variant Caller version
3.2.45211 and Ion Reporter version 1.2. Visual inspection
of the BAM ﬁle from each specimen, including the three
genes for clinical diagnosis and the remainder of the genes
in the AmpliSeq panel, was performed with Integrative
Genomics Viewer (IGV) version 2.3 (Broad Institute,
Cambridge, MA). IGV was used to verify the variants
called and to identify short reads with potential mispriming
events (see Results).
Targeted NGS of Individual Mispriming Sites
For conﬁrmation of the putative mutation sites within EGFR
exons 20 and 21, GNAQ exon 5, ABL1 exon 7, RB1 exon 20,
RET exon 15, SMAD4 exon 6, and APC exon 14, primers were
designed for sequencing on the Ion Torrent PGM platform.
Primer pairs were as follows: 50-TGTCCGGGAACA-
CAAAGACA-30 and 50-CTGGCTCCTTATCTCCCCTC-30
for EGFR exon 20; 50-CGCAGCATGTCAAGATCACA-30
and 50-TGTCAGGAAAATGCTGGCTG-30 for EGFR exon
21; 50-TAACCTTGCAGAATGGTCGATG-30 and 50-AAC-
ACTTACCTCATTGTCTGACT-30 for GNAQ exon 5; 50-
TCTTGCTGCCCGAAACTG-30 and 50-ATGGGCTGTGT-
AGGTGTCC-30 for ABL1 exon 7; 50-TGTGAACGCCTT-
CTGTCTGA-30 and 50-TGGTCCAAATGCCTGTCTCT-30
for RB1 exon 20; 50-AGAAACATCCTGGTAGCTGAGG-30
and 50-CCTGGCTCCTCTTCACGTAG-30 for RET exon 15;
50-GGCAGCCATAGTGAAGGAC-30 and 50-TACTATGA-
TGGTAAGTAGCTGGC-30 for SMAD4 exon 6; and, 50-
TGAAACAGAATCAGAGCAGCC-30 and 50-GACTTTGT-
TGGCATGGCAGA-30 for APC exon 14. For iterative primer
design to minimize mispriming, additional forward primers
were used as follows: 50-GACTTGGCAGCCAGAAACAT-30
(RET F2) and 50-TTTTCCTCACAGCTCGTTCA-30 (RET
F3) for RET exon 15 and 50-TGACAATGGGAATGAAA-
CAGA-30 (APC F2) and 50-GGAAAATGACAATGGGA-
ATGA-30 (APC F3) for APC exon 14. Adaptor sequences Ajmd.amjpathol.org - The Journal of Molecular Diagnostics
Characteristics of NGS False Positives(50-CCATCTCATCCCTGCGTGTCTCCGACTCAG-30) and
P1 (50-CCTCTCTATGGGCAGTCGGTGAT-30) for the Ion
Torrent system were included at the 50 end of the forward and
reverse primers, respectively. Each exon was separately
ampliﬁed with Platinum PCR SuperMix High Fidelity (Life
Technologies), veriﬁed by agarose gel electrophoresis, and
puriﬁed with the QIAquick PCR Puriﬁcation Kit (Qiagen,
Hilden, Germany). The ﬁnal products were pooled, and DNA
was quantiﬁed with a Qubit 2.0 Fluorometer. The Ion One-
Touch 200 Template Kit version 2 DL and the Ion OneTouch
ES Instrument were then used for emulsion PCR and enrich-
ment, and the Ion PGM 200 Sequencing Kit, Ion 318 Chips,
and the PGM sequencing platform for massive parallel
sequencing, as recommended by the manufacturers’ protocols
without modiﬁcation. Sequencing data were analyzed with
Torrent Suite formapping and IGV for evaluation of read depth
and mutational status.
Additional Bioinformatic Analyses
Sequencing data for four specimens were reanalyzed sepa-
rately with Burrows-Wheeler Transform-based mapping
algorithms: Bowtie 2 (Johns Hopkins University, Baltimore,
MD) and Burrows-Wheeler Aligner (BWA; Wellcome Trust
Sanger Institute, Cambridge, UK).15,16 Raw sequencing data
(FASTQ ﬁles) for each specimen were passed through each
algorithm with default settings, and the resulting alignment
ﬁles (BAM format) were coordinated, sorted, and evaluated
with IGV for read depth and mutational status.The Journal of Molecular Diagnostics - jmd.amjpathol.orgStatistical Analysis
All statistical analyses, including Fisher exact tests, Wil-
coxon rank-sum tests, and Kendall correlations, were per-
formed with R version 3.0.1 (R Foundation for Statistical
Computing, Vienna, Austria).
Results
Initial Identiﬁcation of the EGFR Exon 21 G873R
Mutation
Although analyzing sequence data from exons of KRAS,
BRAF, and EGFR, Ion Torrent Variant Caller and/or Ion
Reporter reported an apparent novel mutation in exon 21 of
EGFR, c.2617G>A (p.Gly873Arg, G873R), occurring in up
to 15% of reads, in 23 of our 291 patient samples (15 by both
Ion Torrent Variant Caller and Ion Reporter and 8 by Ion
Reporter alone). This mutation was not reported in COSMIC
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic,
last accessed July 14, 2014). Careful examination of the
actual sequence reads in IGV in all of our cases showed that
this mutation was present in >5% of total reads in 50 of 291
samples. Notably, it was only present in shorter reads. These
reads had a common 50 end, starting in the middle of the
exon 21 amplicon in the AmpliSeq panel, with three single-
base mutations within the ﬁrst 8 bases, whereas the 30 end
matched the full-length amplicon (Figure 1, A and D). This
result indicated that these apparent mutations might be dueFigure 1 Next-generation sequencing mis-
priming events occur at multiple amplicons within
the Cancer Hotspot Panel. Representative screen
capture images from the Integrative Genomics
Viewer showing full-length (top of each panel)
and short, misprimed reads (bottom of each
panel) for EGFR exon 21 (A), RB1 exon 20 (B), APC
exon 14 (C), and detail of the 50 end of EGFR exon
21 (D).
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McCall et alto another primer mispriming within this EGFR exon as a
somewhat nonspeciﬁc reaction, where it contained enough
homology to bind, but where the three bases diverged be-
tween the offending primer and the EGFR off-target
sequence, producing the three apparent mutations. The
mispriming primer participates with the correct EGFR
reverse primer to produce the inappropriate amplicon for
sequencing.
Other Mispriming Events
We then set out to systematically determine whether theEGFR
exon 21 G873R-producing short reads were unique to this
amplicon, or whether similar false-positive mutations were
found in other genes in the AmpliSeq panel. To screen these
genes most effectively, we ﬁrst started with a single specimen
with the best combination of a high number of apparentTable 1 False-Positive Mutations from Nonspeciﬁc Primer Binding
Gene Exon
hg19 Genome
location
Mutation
type Mutation
ABL1 7 9:133750318 Silent C>T
ALK 23 2:29443666 Missense G>A
APC 14 (var1)y 5:112175940 Insertion insA
17 (var2)
16 (var3)
APC 14 (var1)y 5:112175938 Silent A>G
17 (var2)
16 (var3)
ATM 26 11:108155119 Silent A>G
EGFR 20 7:55249168 Silent A>C
EGFR 20 7:55249174 30 intronic A>G
EGFR 21 7:55259559 Missense G>A
EGFR 21 7:55259552 Missense T>G
EGFR 21 7:55259554 Missense C>A
ERBB2 21 (var1)y 17:37881388 Silent A>G
24 (var2)
ERBB2 21 (var1)y 17:37881384 Missense T>A
24 (var2)
GNAQ 5 9:80409443 Missense G>A
GNAQ 5 9:80409448 Insertion insCA
KIT 2 4:55561706 Silent C>A
PDGFRA 18 4:55152043 Silent G>A
RB1 20 13:49033902 Missense A>C
RET 15 (1) 10:43615621 Nonsense T>G
RET 15 (2) 10:43615572 Missense A>T
SMAD4 6 18:48584594 Missense A>T
SMAD4 9 18:48591897 Missense G>C
SMAD4 10 18:48593453 Missense CT>TC
STK11 8 19:1223060 Missense C>A
TP53 5 17:7578556 50 intronic A>T
TP53 8 17:7577106 Missense C>G
*Reported in COSMIC and in the literature via a multiplex PCR NGS panel (see
yVariant transcripts in these genes lead to different exon numbers, cDNA posit
zMutations that have been reported in COSMIC (http://cancer.sanger.ac.uk, last
COSMIC, Catalog of Somatic Mutations in Cancer; NGS, next-generation sequen
544G873R mutations (15.5%) and a large number of EGFR exon
21 reads (2504), reasoning that it offered the optimum chance
to catch these mutations at their highest frequencies, even in
amplicons with lower coverage than EGFR exon 21. By using
a cutoff of 5% of total reads, we identiﬁed 17 sites, with a
similar pattern of mutations generated at the end of short reads,
within the exons of the 50 genes in the panel, along with two
mutations in intronic regions contained within the available
amplicons (Table 1). The most prevalent example, a T224N
mutation in exon 5 of GNAQ, occurred in 19.5% of 2408
reads, whereas mutations in ABL1, APC, ERBB2, and RB1
each happened in >10% of total reads. The various mis-
priming events result in one to three base substitutions
(Figure 1, BeD, respectively), as well as in one or two base
insertions (Table 1). These mispriming events, when identi-
ﬁed, occur at the same positions in every specimen (see
representative examples in Supplemental Table S1).cDNA
position Protein change
Mutant
reads
Total
reads Percent, %
1206 G402G 805 6484 12.42
3551 G1184E* 71 1358 5.23
4594_4595 Frameshift/
truncation
158 1102 14.34
4648_4649
4648_4649
4593 Q1531Qz 151 1091 13.84
4647 Q1549Q
4647 Q1549Q
3912 R1304R 124 2024 6.13
2466 A822A 279 2938 9.50
187 2643 7.08
2617 G873R 388 2504 15.50
2610 H870Q 285 2147 13.27
2612 A871Ez 287 2192 13.09
2580 K860K 252 2151 11.72
2490 K830K
2576 V859D 169 1990 8.49
2486 V829D
671 T224N 470 2408 19.52
666_668 Frameshift/
truncation
242 2118 11.43
96 G32G 107 2134 5.01
2475 L825L 100 1496 6.68
2039 I680T 250 2176 11.49
2700 Y900X 75 781 9.60
2653 E884V* 29 567 5.11
767 Q256L 112 1164 9.62
1060 V354L 187 2308 8.10
1204 L402S 40 508 7.87
997 R333S 61 1066 5.72
371 5357 6.93
835 P279A 26 418 6.22
Discussion).
ions, and amino acid numbers.
accessed July 14, 2014).
cing.
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Characteristics of NGS False PositivesMispriming Events Correspond to Presumptive Primers
in the Cancer Hotspot Panel
As discussed, we hypothesized that these short reads with
mutations generated at one end represented ampliﬁcation
with mismatched primers (Figure 2). We therefore
compared the sequences of the mutated ends of the short
reads with the presumptive PCR primers (by examining the
20 bases on either side of the 50 and 30 ends of the full-
length amplicons). We were able to identify homologous
regions in 18 of the 19 short read sequences, consisting of
10 to 17 bases of sequence, primarily within genomic
sequence immediately 50 or 30 to the ends of the full-length
amplicons (Table 2). Interestingly, a single presumptive
primer, at the 50 end of exon 26 of the KDR gene, produced
both the EGFR G873R events and the equally frequent si-
lent Q1549Q mutation in exon 16 of APC. Careful searching
of the FASTQ data ﬁles of the specimen also found rare
short reads of PIK3CA (9 of 1600 reads) with the same KDR
sequence.Validation of G873R and Other Mispriming Events as
False Positives
To conﬁrm that the presumptive mispriming events we
identiﬁed are not true mutations, we designed PCR primers
to amplify 100 to 150 bases around the eight most common
event sites. By using DNA from the same patient specimen
as used to identify the 19 mispriming sites, we ampliﬁed
each site separately, pooled the products, and sequenced
them with the Ion Torrent PGM. With at least 350,000 reads
for each amplicon, we identiﬁed no short reads with these
mutations and few mutations overall (<0.1%) at each mis-
priming event site (Table 3). Therefore, the mutations seenFigure 2 Model of mispriming events during library ampliﬁcation. A:
The primers recognize the 50 and 30 ends of each amplicon (green) and have
50 adaptors for use in emulsion PCR and sequencing (orange). B: However,
in certain situations, another primer in the mix (red) is partially homolo-
gous to an internal region of the amplicon (mismatches in black). The
resultant product is shorter than full length and contains false-positive
mutations corresponding to the primer mismatches in the middle of the
true amplicon.
The Journal of Molecular Diagnostics - jmd.amjpathol.orgin the Cancer Hotspot Panel are not present in the genomic
DNA of the sample and represent false positives.
Validation of Mispriming Events for Laboratory
Speciﬁcity
To verify that the mispriming events we see in clinical spec-
imens are not a phenomenon unique to a single laboratory, we
analyzed data obtained from an independent laboratory that
runs the Cancer Hotspot Panel on an Ion Torrent PGM. We
received data from12FFPE specimen runs and analyzed them
for three different mispriming events. We were able to detect
at least a low frequency of mispriming events in 8 of the 12
specimens (Supplemental Table S2), which conﬁrms that
these events are not a laboratory-speciﬁc artifact.
Mispriming Events Are Identiﬁed as Mutations by
Multiple Different Alignment Algorithms
To determine whether mispriming events are uniquely
identiﬁed by the Torrent Suite as real mutations, we re-
analyzed the FASTQ sequencing data for four specimens by
using two independent alignment algorithms: Bowtie 2 and
BWA-MEM. Bowtie 2 aligns all of the misprimed reads in a
similar fashion to Torrent Suite, whereas BWA-MEM trims
the misprimed ends from three of the ﬁve mispriming events
where more than one mismatch is present and in both cases
where a one base insertion is produced (Supplemental
Tables S3 and S4). In the 15 mispriming events in which
BWA-MEM does not trim the reads, it maps at least as high
a percentage of reads as Torrent Suite. Thus, mispriming
events remain a pitfall regardless of which alignment algo-
rithm is chosen.
Mispriming Events Are More Common in Samples with
Low DNA Quantity or Few Sequencing Reads
We then sought to determine the frequency of EGFR
G873R events in our entire FFPE patient sample runs. In
291 consecutive patient specimens processed during a
6-month period, the frequency varied from 0% (0 of 2926
reads) to 24.1% (7 of 29 reads), quantiﬁed by using IGV. A
negative correlation was found between input DNA amount
and percentage of G873R reads (P < 0.001, Kendall cor-
relation; t Z 0.38). Furthermore, a signiﬁcantly lower
mispriming percentage was found if 30 ng of input DNA
was used (the optimum recommended DNA input by Life
Technologies; n Z 201; median, 0.3%; range, 0% to
17.8%) than if <30 ng was used (n Z 90; median, 3.6%;
range, 0% to 24.1%; P < 0.001) (Figure 3A). However, no
signiﬁcant difference was found between specimens with
<10 ng (10 ng is the minimum recommended DNA input by
Ion Torrent; n Z 42; median, 1.3%; range, 0% to 19.8%)
and specimens with 10 to 29 ng (n Z 48; median, 4.9%;
range, 0% to 24.1%; PZ 0.11). If a 5% G873R cutoff was
applied, only 10 of 201 cases with 30 ng had >5% G873R,545
Table 2 Nonspeciﬁc Primer Binding Sites and the Corresponding Cancer Hotspot Panel Primers
Mispriming
site Target sequence
Presumptive
primer* Primer sequence Resultant mutant sequence
ABL1 Exon 7 50-GCTGATTTTGGCCTGAGCAGGT-30 MET Exon 19F 50-GCTGATTTTGGTCTTGCCAGAGAC-30 50-TTTGGTCTGAGCAGGTTGAT-30
ALK Exon 23 50-CAGGCTCACCCCAATGCAGCGA-30 HRAS Exon 2R 50-CAGGCTCACCTCTATAGTGGGGTC-30 50-CACCTCAATGCAGCGAACAA-30
APC Exon 16 50-CAAGAGAAAGAGGCAGAAA-30 KDR Exon 26Fy 50-CAGGAAGAAAGAGGCATTTAATGAAA-30 50-CAGGAAGAAAGAGGCAGAAA-30
ATM Exon 26 50-AGGGTACCAGAGACAGTGGGAT-30 ALK Exon 25R 50-AGGGTACCAGGAGATGATGTAAG-
GGAC-30
50-ACCAGGGACAGTGGGATGGC-30
EGFR Exon 20 50-AAAGGTAATCAGTGAAGGGAG-30 RB1 Exon 18R 50-CAAGGTGATCAGTTGGTCCTTC-30 50-CAAGGTGATCAGTGAAGGGA-30
EGFR Exon 21 50-CATGCAGAAGGAGGCAAAGT-30 KDR Exon 26Fy 50-CAGGAAGAAAGAGGCATTTAAT-
GAAA-30
50-CAGGAAGAAAGAGGCAAAGT-30
ERBB2
Exon 21
50-CCCAACCATGTCAAAATTACAG-30 FBXW7
Exon 9R
50-CCCAACCATGACAAGATTTTCCCT-
TACCT-30
50-GACAAGATTACAGACTTCGG-30
GNAQ Exon 5 50-TGTCAGCTCTATCATGTTTCT-30 KDR Exon 7F 50-TCAGTCAACTCTTTTTTTTCAGC-30 50-TCAGTCAACTCTATCATGTT-30
KIT Exon 2 50-AGTCCAGGCGAACCGTCT-
CCACC-30
EGFR Exon 20R
(1 of 2)z
50-AGTCCAGGAGGCAGC-30 50-GTCCAGGAGAACCGTCTCCA-30
PDGFRA
Exon 18
50-CGTCCTGCTGGCACAAGGAAA-30 FGFR3 Exon
14R
50-CGTCCTACTGGCATGACCCCCAC-30 50-ACTGGCACAAGGAAAAATTG-30
RB1 Exon 20 50-TCCAGTTGATATGTTCTA-
ATCTG-30
SMAD4
Exon 3R
50-TCCAGGTGATACAACTCGTT-30 50-CCAGGTGATATGTTCTAATC-30
RET Exon
15 (1)
50-TGAAGAGGATTCCTACGTGAAG-30 KDR Exon 27F 50-GGAAGAGGATTCTGGACTCTCT-30 50-GGAAGAGGATTCCTACGTGA-30
RET Exon
15 (2)
50-GGTAGCTGAGGGGCGGAAGAT-30 VHL Exon 1R 50-GGTAGCTGTGGATGCGGCGGCTC-30 50-AGCTGTGGGGCGGAAGAT-30
SMAD4
Exon 10
50-AGGCACCTGACCCAAACATCAC-30 CSF1 Exon 22F 50-GAGCACCTGACCTGCTGCGAGC-30 50-GAGCACCTGACCCAAACATC-30
SMAD4
Exon 6
50-TAGCTGGCTGACCAGTAAATCC-30 PTEN Exon 7R
(1 of 2)z
50-TAGCTGGCAGACCAC-30 50-TGGCAGACCAGTAAATCCAT-30
SMAD4
Exon 9
50-AGGGTCCACGTATCCATCAACA-30 APC Exon 14F
(6 of 7)z
50-AGGGTCCAGGTTCTTCCAGATGCT-30 50-CCAGGTATCCATCAACAGTA-30
STK11 Exon 8 50-GCGCAGCATGACTGTGGTGCCG-30 Not identifiedx 50-GAGCAGCATGACTGTGGTGC-30
TP53 Exon 5 50-GGGAGTACTGTAGGAAGAGGA-30 SMO Exon 5F 50-GGGAGTACAGAGTGACCGCCTC-30 50-ACAGTAGGAAGAGGAAGAAG-30
TP53 Exon 8 50-GACAGGCACAAACACGCACCTC-30 HNF1A
Exon 4F
50-CACAGGCACAGGGGCTG-30 50-CACAGGCACAAACACGCACC-30
Italicized sequence indicates genomic sequence 50 to start of amplicon, bold sequence indicates overlap between presumptive primers and target amplicons,
and underlined sequence indicates mismatched bases generating false-positive mutations.
*Primer sequence presumed to be located immediately 50 to the generated amplicon sequence because of the trimming that takes place after library
ampliﬁcation.
yThe same primer produces both events.
zMultiple amplicons are used in the Cancer Hotspot Panel kit to cover these exons.
xNo sequence present within 20 bases of any amplicon in the Cancer Hotspot Panel corresponds to this short read event.
McCall et alwhereas 40 of 90 cases with <30 ng had >5% (P < 0.001).
If the same 5% G873R cutoff was applied along with the
minimum recommended input DNA of 10 ng, 34 of 252
cases with >10 ng showed >5% G873R compared with 16
of 39 cases with <10 ng (P < 0.001).Table 3 Targeted Sequencing of Misprimed Exons Demonstrates False
Mispriming site*
Cancer Hotspot Panel Targeted s
Mutant
reads
Total
reads
Percent,
%
Short read
with muta
ABL1 Exon 7 805 6484 12.42 0
APC Exon 14 158 1102 14.34 0
EGFR Exon 20 279 2938 9.50 0
EGFR Exon 21 388 2504 15.50 0
GNAQ Exon 5 470 2408 19.52 0
RET Exon 15 75 781 9.60 0
RB1 Exon 20 250 2176 11.49 0
SMAD4 Exon 6 112 1164 9.62 0
*Monoplex PCR reactions.
546The number of sequence reads, which positively corre-
lates with input DNA (P < 0.001; tZ 0.20), also played a
role in this phenomenon and inversely correlated with the
percentage of G873R reads (P < 0.001; t Z 0.22).
Signiﬁcantly fewer mispriming events were found if >500-Positive Nature of Mutations
equencing with custom primer set
P value
s
tion
All mutant
reads
Total
reads
Percent,
%
471 575757 0.082 <1  105
1353 357411 0.38
123 549422 0.022
303 454039 0.067
314 480009 0.066
37 490998 0.008
285 628279 0.045
37 519439 0.007
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Figure 3 Next-generation sequencing mispriming events correlate with
low input DNA and low read depth. Modiﬁed box plots of input DNA (A) and
read depth (B) versus percentage of misprimed reads at EGFR exon 21
(G873R). The horizontal line in the middle of each box indicates the median,
and the top and bottom borders of the box mark the 75th and 25th per-
centiles, respectively. The whiskers above and below the box mark the 90th
and 10th percentiles. Outliers (1.5  interquartile range) are represented
as individual dots. **P < 0.01, ***P < 0.001, Wilcoxon rank-sum test.
Characteristics of NGS False Positivesreads were achieved (the minimum number needed to detect
a 5% mutant allele frequency at 95% conﬁdence; n Z 256;
median, 0.32%; range, 0% to 17.4%) than if <500 reads
were achieved (n Z 35; median, 10.0%; range, 0% to
24.1%; P < 0.001) (Figure 3B). However, no signiﬁcant
difference was found between specimens with 150 or fewer
reads (the minimum needed to detect a 10% mutant allele
frequency at 95% conﬁdence; n Z 23; median, 10.3%;
range, 0% to 24.1%) and specimens with between 151 and
500 reads (n Z 12; median, 7.6%; range, 0% to 14.2%;
P Z 0.44). With the use of a 5% G873R cutoff, 17 of 35
cases with <500 reads showed >5% G873R, whereas only
13 of 256 cases with >500 reads fell into the same category
(P < 0.001). With a cutoff of 150 reads, 12 of 23 cases with
<150 reads had >5% G873R, whereas 18 of 268 cases with
>150 reads showed the same (P < 0.001). Repeat testing of
samples generating this phenomenon showed variability in
the percentage of mispriming events.Figure 4 Model for iterative primer design for multiplex PCR reactions
using NGS. Because the majority of primers do not demonstrate mispriming
events, initial primers can be designed and replaced on the basis of iter-
ative mispriming event analyses. NGS, next-generation sequencing.Multiplex PCR Permits Mispriming Events
We then considered whether the mispriming events were
intrinsic to the AmpliSeq kit or a fundamental problem of
multiplex PCR reactions. To test this, we assembled a
multiplex PCR reaction by using the eight primer pairs used
in separate PCR reactions described above. We found
mispriming events in this custom reaction, conﬁrming that
this is an intrinsic problem of multiplex PCR reactions when
analyzed by NGS. We then designed two new primers to
remove the homology that produced the mispriming events
in the ﬁrst custom reaction. A multiplex reaction, including
these replacement primers, eliminated the identiﬁed mis-
priming events but generated a new one. When this primer
was again replaced, there were no mispriming events (data
not shown).
In this regard, traditional Sanger sequencing or pyrose-
quencing reactions are inherently forgiving because of theirThe Journal of Molecular Diagnostics - jmd.amjpathol.orgpoorer limits of detection. If a primer produces off target
amplicons, but these amplicons are <5% of the total, they
will not be seen. With NGS, because what is being
sequenced is a clone of molecules (produced on the surface
of a bead or a chip) from a single starting molecule, all
products may be seen, and errors generated by the ﬁrst
round of PCR (library preparation) are seen. Although
worrisome at a ﬁrst approximation, this fact should allow
one to iteratively design multiplex PCR reactions by
replacing primers that promiscuously bind to other ampli-
cons in the kit (Figure 4).Discussion
NGS platforms will revolutionize clinical practice by
providing cost-effective, rapid, and sensitive sequencing of
large panels of amplicons important for cancer diagnosis,
prognosis, and therapeutics. However, as we implemented
multiplex PCR-based NGS to detect mutations in colon and
lung cancer specimens, we commonly encountered false-
positive mutations, especially in patient samples with low
DNA amounts or shallow read depths. This phenomenon
occurs uniformly at the 50 or 30 end of short reads, where a
primer among the hundreds in the Cancer Hotspot Panel
anneals to a homologous sequence, with one to three mis-
matches, in the middle of one of the other panel amplicons
(Figure 2). Long reads never contain these mutations, and
they are not present in the genomic DNA targets. Mecha-
nistically, we cannot distinguish whether these events
happen with primer binding to genomic DNA directly or to
the ampliﬁcation product as it increases in concentration
during PCR, although the latter seems more plausible. It is
these mismatches that, on library ampliﬁcation, lead to
mutations that could erroneously be interpreted as existing
within the patient’s tumor DNA. But, because these false
positives occur consistently from sample to sample, in the
same locations, within the same amplicons, and in reads that
are shorter than full length, we are able to easily exclude
them bioinformatically as we sign out patient samples. We547
Table 4 Summary of the Characteristics of Misprimed False-Positive Events
Read length Always shorter than full-length amplicon, with one end identical to full length and
the other in the middle of the target amplicon
False-positive mutation site(s) Within 10 bases of either end of the read
Homology with presumed panel primers 10e17 bases, with 1e3 mismatches
Mutation types Base substitutions and short (1e2 base) insertions
McCall et altabulated the critical features of mispriming events that
distinguish them from true amplicons (Table 4).
We also reviewed PubMed and COSMIC for mutations
reported at mispriming event sites to see whether these
events had been identiﬁed by others. We identiﬁed three
references to mutations at these sites: two of these either did
not use NGS or the AmpliSeq panel, whereas ALK G1184E
and RET E884V were reported in one thymic squamous cell
carcinoma case.17 The thymic carcinoma case is instructive:
IGV screen shots of three mutations were published, and the
two mutations which we found in mispriming events, ALK
G1184E and RET E884V, are seen only at the ends of short
reads, whereas the third intronic variant, TP53 c.782þ1
G>T, which we did not identify, is displayed in full-length
reads. Although we have not reviewed the primary data in
this case, and the methods are not completely speciﬁed, we
are concerned that these two of the three reported mutations
may represent false positives due to mispriming, which
underscores the need to identify this phenomenon while
analyzing multiplex PCR-based NGS data.
The existence of reproducible false-positive mutations in
the Cancer Hotspot Panel brings up three major areas of
concern: data analysis, sample DNA quantity, and the
speciﬁcity of massively multiplex PCR reactions. Given the
large number of amplicons in this and other targeted gene
panels, it is time consuming and ultimately impractical to
manually read each sequence. As such, automated software
such as Ion Torrent’s Variant Caller is essential to the future
of this technology in a clinical laboratory. However, in our
experience, the current version of Variant Caller is unable to
distinguish between a true point mutation and one intro-
duced by a mispriming event, requiring us to examine se-
quences manually by using the IGV. One possible way to
remedy this issue would be to analyze only full-length
amplicons, because most of the mispriming events result in
much shorter amplicon lengths. This would eliminate these
false positives, but at the same time would reduce the total
number of reads, and therefore the sensitivity of mutation
detection, because a signiﬁcant number of shorter reads
with correct priming would be ﬁltered out. Another
approach would be to design software to automatically
screen out the mispriming mutations, as they occur in
consistent locations in the panel, allowing for short reads to
be included in read depth and sensitivity to be maintained.
Finally, a third approach would be to identify and eliminate
offending primers during kit development. In this regard,
NGS may be the ultimate multiplex primer design tool
because one could initially design primers, then use NGS to548identify and replace promiscuous primers iteratively, as
shown in Figure 4.
Our results emphasize the importance of using a sufﬁcient
quantity of DNA to ensure accurate results in Ion Torrent-
based NGS. In samples in which <30 ng of DNA were
available for use, the number of mispriming events was
signiﬁcantly higher. Interestingly, these events were not re-
ported by a clinical validation study that used the same panel,
whereby only 10 ng of DNA was used in each case.11 It is
unclear whether the short reads we found were screened out in
the data analysis of Singh et al.11 If not, there are other pos-
sibilities for the discrepancy: we used a different manufac-
turer’s DNA extraction kit and used Ion Torrent’s automated
One Touch emulsion PCR system. Singh et al11 reported
signiﬁcantly higher quality reads (as determined by the
average AQ20 reads per sample) by using a manual emulsion
PCR method. In this regard, the instructions for the kit
recommend 10 to 30 ng of input DNA, whereas we ﬁnd fewer
mispriming artifacts by using 30 ng.
Our analysis also included 39 patient samples in which
we were unable to reach 10 ng of DNA input. A major
question is whether to run these samples at all, because of
the increased incidence of misprimed false-positive muta-
tions. But we were able to achieve read depths of >150
reads in 28 of 39 samples and >500 reads in 25 of 39
samples, allowing for adequately sensitive detection of true
mutations. Because of the difﬁculty of obtaining more DNA
in many cases, especially from ﬁne-needle aspirations and
small biopsies, we have attempted to run samples with low
DNA content in the hope of obtaining useable results. In
about three-quarters of cases, we have been successful.
However, one concern with low DNA quantity in cases in
which read depth appears adequate (or even excellent) is
that a small number of DNA molecules are being prefer-
entially ampliﬁed. One could imagine a case in which a ﬁne-
needle aspiration contained 10% tumor cells with a coding
mutation in a panel amplicon, but with few cells overall. If
the DNA from benign stromal cells was preferentially
ampliﬁed, a false negative would be produced; conversely,
if the DNA from tumor cells was preferentially ampliﬁed, a
falsely high mutation percentage could be obtained, leading
to incorrect assignment of a germline mutation. Moreover,
the quality of the DNA used may also play a role in this
assay. We have samples in which more than adequate DNA
amounts were used (30 ng), but read depth was poor and/or
a high percentage of mispriming events occurred. Perhaps in
these cases, the DNA was more highly fragmented, leading
to poor ampliﬁcation.jmd.amjpathol.org - The Journal of Molecular Diagnostics
Characteristics of NGS False PositivesFinally, our data indicate a ﬂaw in using massively
multiplex PCR reactions, with hundreds of primers, to
amplify many different amplicons simultaneously before
DNA sequencing. Multiplex PCR requires careful primer
design to avoid signiﬁcant homology between amplicons and
primers.18,19 In cases in which the stoichiometry of the re-
action shifts toward more primer concentration in relation to
template (ie, low DNA quantity), we hypothesize that primer
binding to these partially homologous internal targets occurs
at a high frequency to generate the short reads that we ﬁnd.
As more amplicons are included in larger and more
comprehensive exon panels, we are concerned that this
phenomenon may be even more common, because the like-
lihood of partial homology goes up with increasing numbers
of primers and amplicons. One could use a multiplex reaction
as a primer design tool of sorts, whereby primers for different
exons could be tested iteratively to minimize mispriming
events and to maximize read depth. Whole exome
sequencing, provided that it achieves adequate depth of
coverage to detect small mutation percentages in tumor
samples, could resolve this problem by eliminating the
ampliﬁcation step, but it is likely that larger quantities of
DNA (and therefore larger samples) will be needed.
In summary, we have identiﬁed a consistent pattern of
mispriming events that produce false-positive mutations in Ion
Torrent-based NGS by using a multiplex PCR-based targeted
gene panel. These events are more common in samples with
shallow read depth and low DNA quantity. Such low amounts
of tumor DNA are often unavoidable in clinical situations in
which small biopsies and ﬁne-needle aspirations for tumor
diagnosis are used. The mispriming events occur in consistent
locations from sample to sample and occur only in short reads,
allowing them to be easily identiﬁed. As NGS platforms come
into wider use in molecular diagnostics, phenomena such as
thismust be recognized to avoid signiﬁcant diagnostic errors in
clinical practice. The AmpliSeq cancer panel is a valuable new
tool for molecular diagnostics laboratories, and we present a
number of options to circumvent this issue.Acknowledgments
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